Clinical trial data validate the C-peptide estimate model in type 1 diabetes.
作者信息
Wentworth John M, Bediaga Naiara G, Gitelman Stephen E, Evans-Molina Carmela, Gottlieb Peter A, Colman Peter G, Haller Michael J, Harrison Leonard C
机构信息
Royal Melbourne Hospital Department of Diabetes and Endocrinology, Parkville, VIC, Australia.
Royal Melbourne Hospital Department of Medicine, University of Melbourne, Parkville, VIC, Australia.
出版信息
Diabetologia. 2020 Apr;63(4):885-886. doi: 10.1007/s00125-020-05088-6. Epub 2020 Jan 26.
Abstract
摘要
相似文献
1
Clinical trial data validate the C-peptide estimate model in type 1 diabetes.临床试验数据验证了1型糖尿病中C肽估计模型。
Diabetologia. 2020 Apr;63(4):885-886. doi: 10.1007/s00125-020-05088-6. Epub 2020 Jan 26.
2
Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.低剂量抗胸腺细胞球蛋白可保存 C 肽、降低 HbA1c，并增加新发 1 型糖尿病患者调节性 T 细胞与常规 T 细胞的比值：两年临床试验数据。
Diabetes. 2019 Jun;68(6):1267-1276. doi: 10.2337/db19-0057. Epub 2019 Apr 9.
3
Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.抗胸腺细胞球蛋白/粒细胞集落刺激因子治疗可保留已确诊1型糖尿病患者的β细胞功能。
J Clin Invest. 2015 Jan;125(1):448-55. doi: 10.1172/JCI78492. Epub 2014 Dec 15.
4
Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.抗胸腺细胞球蛋白联合粒细胞集落刺激因子治疗对部分已确诊1型糖尿病的应答者产生持续的免疫调节和代谢作用。
Diabetes. 2016 Dec;65(12):3765-3775. doi: 10.2337/db16-0823. Epub 2016 Sep 26.
5
Mixed-meal tolerance test to assess residual beta-cell secretion: Beyond the area-under-curve of plasma C-peptide concentration.混合餐耐量试验评估胰岛β细胞分泌功能：不仅仅是基于血浆 C 肽浓度曲线下面积。
Pediatr Diabetes. 2019 May;20(3):282-285. doi: 10.1111/pedi.12816. Epub 2019 Feb 19.
6
Mobilization without immune depletion fails to restore immunological tolerance or preserve beta cell function in recent onset type 1 diabetes.在近期发病的1型糖尿病中，无免疫清除的动员不能恢复免疫耐受或维持β细胞功能。
Clin Exp Immunol. 2016 Mar;183(3):350-7. doi: 10.1111/cei.12731. Epub 2015 Dec 7.
7
C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet.在 TrialNet 中，对 1 型糖尿病诊断前后进行长期随访的受试者的 C 肽水平。
Diabetes Care. 2020 Aug;43(8):1836-1842. doi: 10.2337/dc19-2288. Epub 2020 May 26.
8
Interleukin-1 antagonism in type 1 diabetes of long duration.长期1型糖尿病中的白细胞介素-1拮抗作用。
Diabetes Metab. 2016 Dec;42(6):453-456. doi: 10.1016/j.diabet.2016.08.005. Epub 2016 Oct 5.
9
Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP).胰岛新生相关蛋白（INGAP）衍生肽对1型和2型糖尿病的治疗效果。
Diabetes Metab Res Rev. 2009 Sep;25(6):558-65. doi: 10.1002/dmrr.999.
10
Persistent C-peptide is associated with reduced hypoglycaemia but not HbA in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice?长期 1 型糖尿病成人患者中，持续 C 肽与低血糖减少相关，但与 HbA 无关：英国临床实践中缺乏强化治疗的证据？
Diabet Med. 2019 Sep;36(9):1092-1099. doi: 10.1111/dme.13960. Epub 2019 Jun 27.
引用本文的文献
1
Approaches to Measuring Beta Cell Reserve and Defining Partial Clinical Remission in Paediatric Type 1 Diabetes.测量儿童1型糖尿病β细胞储备及定义部分临床缓解的方法
Children (Basel). 2024 Feb 2;11(2):186. doi: 10.3390/children11020186.
本文引用的文献
1
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.抗 CD3 抗体，特利珠单抗，用于 1 型糖尿病风险亲属。
N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9.
2
Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables.1 型糖尿病患者的β细胞功能由临床和空腹生化变量决定。
Diabetologia. 2019 Jan;62(1):33-40. doi: 10.1007/s00125-018-4722-z. Epub 2018 Aug 30.
3
Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA in New-Onset Type 1 Diabetes.低剂量抗胸腺细胞球蛋白 (ATG) 可维持β细胞功能并改善初诊 1 型糖尿病患者的 HbA1c。
Diabetes Care. 2018 Sep;41(9):1917-1925. doi: 10.2337/dc18-0494. Epub 2018 Jul 16.
4
Partial remission definition: validation based on the insulin dose-adjusted HbA1c (IDAA1C) in 129 Danish children with new-onset type 1 diabetes.部分缓解的定义：基于胰岛素剂量调整后的糖化血红蛋白（IDAA1C）对129名丹麦新发1型糖尿病儿童进行验证。
Pediatr Diabetes. 2014 Nov;15(7):469-76. doi: 10.1111/pedi.12208.
5
Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes.在1型糖尿病治疗试验中，混合餐耐量试验与胰高血糖素刺激试验对β细胞功能的评估
Diabetes Care. 2008 Oct;31(10):1966-71. doi: 10.2337/dc07-2451. Epub 2008 Jul 15.
Zotero 插件